Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
palliative care
hormonal therapy off-label uses |
| gptkbp:contraindication |
pregnancy
breastfeeding |
| gptkbp:dosage_form |
injectable
|
| gptkbp:drug_interactions |
anticoagulants
antidiabetic medications CYP3 A4 inhibitors |
| gptkbp:duration |
up to 6 months
long-term therapy possible |
| gptkbp:effective_date |
gptkb:2000
|
| gptkbp:formulation |
sustained-release
|
| gptkbp:frequency |
once a month
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eligard 7.5 mg
|
| gptkbp:indication |
gptkb:endometriosis
precocious puberty uterine fibroids |
| gptkbp:ingredients |
gptkb:leuprolide_acetate
|
| gptkbp:is_monitored_by |
lipid profile
PSA levels testosterone levels blood glucose |
| gptkbp:manufacturer |
gptkb:Taro_Pharmaceuticals
|
| gptkbp:mechanism_of_action |
Gn RH agonist
|
| gptkbp:packaging |
single-use prefilled syringe
|
| gptkbp:patient_education |
regular follow-up appointments
avoid pregnancy during treatment report severe side effects importance of adherence to schedule |
| gptkbp:patient_population |
pediatric patients
adult men |
| gptkbp:pharmacokinetics |
excreted in urine
subcutaneous absorption metabolized in liver decreases testosterone production reduces estrogen levels |
| gptkbp:route_of_administration |
subcutaneous
subcutaneous injection |
| gptkbp:safety_features |
generally well tolerated
monitor for adverse effects |
| gptkbp:service_frequency |
monthly
|
| gptkbp:side_effect |
fatigue
nausea weight gain injection site reactions hot flashes |
| gptkbp:storage |
refrigerated
|
| gptkbp:strength |
7.5 mg
|
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:bfsParent |
gptkb:Eligard
|
| gptkbp:bfsLayer |
6
|